In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bayer AG

www.bayer.com

Latest From Bayer AG

Novartis Tunes Into Radiopharmaceuticals With Endocyte Buy

Endocyte paid just $12m upfront a year ago for a potential first-in-class investigational radioligand therapy for prostate cancer. Novartis is buying Endocyte for a whopping $2.1bn., highlighting the company's emphasis on building in radiopharmaceuticals.

M & A Cancer

A Long March After Approval: What You Need To Launch Orphan Drugs In China

Without automatic reimbursement in place, makers of orphan and rare disease drugs must look at innovative alternative ways to make their high-priced new therapies accessible to patients in China.

China Business Strategies

Early-Stage Cell And Gene Therapy Progress: Updates From Casebia, BlueRock, Athersys, Cynata

Scrip caught up with several companies during the recent Cell and Gene Meeting on the Mesa, sponsored by the Alliance for Regenerative Medicine.

Regenerative Medicine Business Strategies

Key Cancer Data To Be Unveiled At ESMO In Munich

Big pharma and little biotechs are getting ready to pack their bags for Germany where over 2,000 abstracts will be presented at ESMO and the fine details on some major oncology studies will be closely watched.

Cancer Clinical Trials
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register